- Home
- GLQ vs EQ Comparison
GLQ vs EQ Comparison
Compare GLQ & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | EQ |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.2M | 140.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLQ | EQ |
|---|---|---|
| Price | $7.83 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 38.5K | ★ 385.8K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.27 | $0.76 |
| 52 Week High | $8.75 | $3.54 |
Technical Indicators
Market Signals| Indicator | GLQ | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 30.42 | 40.88 |
| Support Level | $7.65 | $1.97 |
| Resistance Level | $8.18 | $2.58 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 5.88 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.